BrainsWay Ltd. (TLV:BWAY)
Israel
· Delayed Price · Currency is ILS · Price in ILA | Market Cap | 623.44M |
| Revenue (ttm) | 149.39M |
| Net Income (ttm) | 10.64M |
| Shares Out | 37.74M |
| EPS (ttm) | 0.20 |
| PE Ratio | 81.92 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,083 |
| Average Volume | 31,511 |
| Open | 1,610.00 |
| Previous Close | 1,610.00 |
| Day's Range | 1,610.00 - 1,700.00 |
| 52-Week Range | 951.00 - 2,080.00 |
| Beta | 0.16 |
| RSI | 49.88 |
| Earnings Date | May 12, 2025 |
About BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves do... [Read more]
News
BrainsWay: Strong Growth Prospects Matter Little To The Market
BrainsWay Ltd. (BWAY) Q4 2024 Earnings Call Transcript
BrainsWay Ltd. (NASDAQ:BWAY) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Hadar Levy - Chief Executive Officer ...
BrainsWay GAAP EPS of $0.04 beats by $0.02, revenue of $11.41M beats by $0.52M
BrainsWay reports Q4 GAAP EPS of $0.04, revenue up 26.4% Y/Y, and strong 2025 guidance. Growth in Deep TMS™ adoption driving profitability.
BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Achieved r ecord quarterly s ales of $11.4 million in Q4 2024 , an increase of 27% compared with Q4 2023
Earnings Scheduled For March 11, 2025
Companies Reporting Before The Bell • Exagen (NASDAQ: XGN) is projected to report quarterly loss at $0.24 per share on revenue of $13.85 million. • Core Molding Technologies (AMEX: CMT) is expected ...
BrainsWay Q4 2024 Earnings Preview
BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder
BURLINGTON, Mass. and JERUSALEM, Dec. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain ...
BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy
BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd.
BrainsWay: Cash Flow Doubts Weigh On The Stock
BrainsWay reported strong growth in the third quarter and gave solid guidance. Click here to read my analysis of BWAY stock.
BrainsWay Ltd. (BWAY) Q3 2024 Earnings Call Transcript
BrainsWay Ltd. (NASDAQ:BWAY) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Hadar Levy - CEO Ido Marom - CFO Conference Call P...
BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights
Robust 26% Year-over-Year Revenue Growth in Q3 2024 Raising Full-Year 2024 Revenue Guidance to $40-41 Million and Initiating Profitability Guidance Conference Call to be Held Today at 8:30 AM ET BURLI...
Earnings Scheduled For November 12, 2024
Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ: TIGR) is likely to report quarterly earnings at $0.13 per share on revenue of $98.00 million. • PLDT (NYSE: PHI) is likely to report...
BrainsWay Q3 Earnings Preview
BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024
BURLINGTON, Mass. and JERUSALEM, Oct. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
Are Medical Stocks Lagging Brainsway This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Brainsway Ltd. Sponsored ADR (NASDAQ: BWAY) been one of thos...
BrainsWay Further Penetrates East Asia with Placement of 15 Additional Deep TMS™ Systems in Taiwan and South Korea
BURLINGTON, Mass. and JERUSALEM, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay: More Cash, More Uncertainty
What's Going On With BrainsWay Shares Monday?
BrainsWay Ltd. (NASDAQ: BWAY) stock is trading higher on Monday after the company announced a $20 million investment from Valor Equity Partners. The Details: BrainsWay will issue a total of 2,103,745...
BrainsWay Announces US$20 Million Private Placement with Valor Equity Partners
Company to leverage capital and Valor's expertise for strategic initiatives building market awareness, R&D roadmap, data analysis capabilities, and expanding access to Deep TMS™
BrainsWay announces expansion of Deep TMS platform along East Coast
BrainsWay Announces Significant Expansion on U.S. East Coast
BURLINGTON, Mass. and JERUSALEM, Sept.
Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli Hospitals
BURLINGTON, Mass. and JERUSALEM, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulatio...
BrainsWay appoints Richard Bermudes, M.D. as CMO
BrainsWay (BWAY) has announced the appointment of Richard A. Bermudes, M.D. as Chief Medical Officer, effective Sept. 1, 2024
BrainsWay Appoints Richard A. Bermudes, M.D.
Dr. Bermudes is Widely Considered One of the Preeminent U.S. Clinicians in the TMS Field Dr. Bermudes is Widely Considered One of the Preeminent U.S. Clinicians in the TMS Field